ANI Pharmaceuticals (NASDAQ:ANIP) Issues Earnings Results

ANI Pharmaceuticals (NASDAQ:ANIP) announced its quarterly earnings results on Friday. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.30, Briefing.com reports. The company had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company’s revenue for the quarter was up 53.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.34 earnings per share. ANI Pharmaceuticals updated its FY 2025 guidance to 7.370-7.640 EPS.

ANI Pharmaceuticals Stock Up 0.2%

Shares of ANI Pharmaceuticals stock traded up $0.20 during trading hours on Friday, reaching $90.43. 710,592 shares of the company’s stock were exchanged, compared to its average volume of 369,356. The stock has a market cap of $1.96 billion, a P/E ratio of -117.44 and a beta of 0.54. The company has a 50 day moving average of $93.64 and a two-hundred day moving average of $77.38. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $99.50.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Truist Financial upped their price target on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. JPMorgan Chase & Co. increased their target price on ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Finally, HC Wainwright upped their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $99.14.

Insider Activity at ANI Pharmaceuticals

In related news, Director Matthew J. Leonard sold 2,528 shares of the business’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $90.62, for a total transaction of $229,087.36. Following the transaction, the director directly owned 6,864 shares in the company, valued at approximately $622,015.68. The trade was a 26.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Muthusamy Shanmugam sold 52,988 shares of the company’s stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $90.44, for a total transaction of $4,792,234.72. Following the sale, the chief operating officer directly owned 431,920 shares in the company, valued at $39,062,844.80. This trade represents a 10.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 413,830 shares of company stock worth $36,505,378. Insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. CANADA LIFE ASSURANCE Co increased its position in ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 198 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in ANI Pharmaceuticals by 2.6% during the second quarter. Thrivent Financial for Lutherans now owns 12,511 shares of the specialty pharmaceutical company’s stock worth $816,000 after purchasing an additional 321 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares during the period. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 470 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.